Atai Life Sciences N.V. 9VC.F Stock
Atai Life Sciences N.V. Price Chart
Atai Life Sciences N.V. 9VC.F Financial and Trading Overview
Atai Life Sciences N.V. stock price | 2.29 EUR |
Previous Close | 1.62 EUR |
Open | 1.61 EUR |
Bid | 1.61 EUR x N/A |
Ask | 1.66 EUR x N/A |
Day's Range | 1.61 - 1.61 EUR |
52 Week Range | 1.07 - 4.84 EUR |
Volume | 320 EUR |
Avg. Volume | 3.22K EUR |
Market Cap | 267.94M EUR |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.23 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 29.1 EUR |
9VC.F Valuation Measures
Enterprise Value | 49.43M EUR |
Trailing P/E | N/A |
Forward P/E | -1.6639174 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 992.37085 |
Price/Book (mrq) | 1.131044 |
Enterprise Value/Revenue | 183.072 |
Enterprise Value/EBITDA | -0.351 |
Trading Information
Atai Life Sciences N.V. Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -43.29% |
S&P500 52-Week Change | 20.43% |
52 Week High | 4.84 EUR |
52 Week Low | 1.07 EUR |
50-Day Moving Average | 1.7 EUR |
200-Day Moving Average | 2.38 EUR |
9VC.F Share Statistics
Avg. Volume (3 month) | 3.22K EUR |
Avg. Daily Volume (10-Days) | 609 EUR |
Shares Outstanding | 166.01M |
Float | 133.3M |
Short Ratio | N/A |
% Held by Insiders | 9.26% |
% Held by Institutions | 31.44% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -52222.97% |
Gross Margin | 100.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -26.52% |
Return on Equity (ttm) | -51.83% |
Income Statement
Revenue (ttm) | 270K EUR |
Revenue Per Share (ttm) | 0.002 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 233K EUR |
EBITDA | -140828992 EUR |
Net Income Avi to Common (ttm) | -148651008 EUR |
Diluted EPS (ttm) | -0.91 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 249.88M EUR |
Total Cash Per Share (mrq) | 1.51 EUR |
Total Debt (mrq) | 19.01M EUR |
Total Debt/Equity (mrq) | 7.9 EUR |
Current Ratio (mrq) | 13.428 |
Book Value Per Share (mrq) | 1.427 |
Cash Flow Statement
Operating Cash Flow (ttm) | -101592000 EUR |
Levered Free Cash Flow (ttm) | -55344000 EUR |
Profile of Atai Life Sciences N.V.
Country | Germany |
State | N/A |
City | Berlin |
Address | Wallstrasse 16 |
ZIP | 10179 |
Phone | 49 89 2153 9035 |
Website | https://www.atai.life |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 133 |
ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
Q&A For Atai Life Sciences N.V. Stock
What is a current 9VC.F stock price?
Atai Life Sciences N.V. 9VC.F stock price today per share is 2.29 EUR.
How to purchase Atai Life Sciences N.V. stock?
You can buy 9VC.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Atai Life Sciences N.V.?
The stock symbol or ticker of Atai Life Sciences N.V. is 9VC.F.
Which industry does the Atai Life Sciences N.V. company belong to?
The Atai Life Sciences N.V. industry is Biotechnology.
How many shares does Atai Life Sciences N.V. have in circulation?
The max supply of Atai Life Sciences N.V. shares is 166.03M.
What is Atai Life Sciences N.V. Price to Earnings Ratio (PE Ratio)?
Atai Life Sciences N.V. PE Ratio is now.
What was Atai Life Sciences N.V. earnings per share over the trailing 12 months (TTM)?
Atai Life Sciences N.V. EPS is -0.23 EUR over the trailing 12 months.
Which sector does the Atai Life Sciences N.V. company belong to?
The Atai Life Sciences N.V. sector is Healthcare.